SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA mutant tumors Meeting Abstract
| Authors: | Baselga, J.; Cortes, J.; De Laurentiis, M.; Dieras, V.; Harbeck, N.; Im, Y. H.; Jacot, W.; Krop, I. E.; Verma, S.; Wilson, T. R.; Lin, R.; Schimmoller, F.; Hsu, J. Y. |
| Abstract Title: | SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA mutant tumors |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036904821 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2015.33.15_suppl.tps629 |
| Notes: | Meeting Abstract: TPS629 -- Source: Wos |
